HeartBeam (NASDAQ: BEAT) has announced the launch of a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, conditions that remain leading causes of death worldwide. The study marks a significant step in the development of the HeartBeam patch, which could disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease continues to pose a serious health threat, contributing to millions of deaths annually and often progressing silently until a major cardiac event occurs. As healthcare providers seek faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology offers a potential solution. The patch is designed to generate on-demand 12-lead ECGs, a clinical-grade diagnostic tool traditionally available only in clinical settings.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG and detecting ischemia from a patch could significantly improve patient outcomes by enabling earlier intervention.”
The pilot study will focus on evaluating the patch's ability to detect inadequate blood flow and oxygen supply to tissue, known as ischemia, which is a key indicator of coronary artery disease. If successful, the HeartBeam patch could provide a non-invasive, convenient method for continuous monitoring of high-risk patients, potentially reducing the need for in-hospital testing and enabling remote patient management.
The implications of this technology are far-reaching. For patients with known or suspected coronary artery disease, the ability to generate a 12-lead ECG on demand from a wearable patch could allow for earlier detection of ischemic events, leading to timely medical intervention. For the healthcare industry, the patch could reduce the burden on emergency departments and cardiology clinics by enabling remote monitoring and reducing unnecessary visits. For the world, it could help address the growing cardiovascular disease epidemic by making advanced diagnostic tools more accessible.
HeartBeam's announcement comes as the company continues to advance its technology in the competitive ambulatory monitoring market. The company's newsroom provides the latest updates and information at https://ibn.fm/BEAT. For full terms of use and disclaimers, visit http://IBN.fm/Disclaimer.
